跳至主要内容
临床试验/CTRI/2023/06/054109
CTRI/2023/06/054109尚未招募2/3 期

An open label double arm controlled clinical study of viddhakarma & pathyadi kwatha in the management of Ardhavabhedaka (Migraine )

未提供1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年6月26日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
入组人数
40
试验地点
1
主要终点
Migraine

研究概览

简要总结

It is a randomized open label double arm controlledclinical study to compare the efficacy of Viddha karma  during pain phase followed by which oraladministration of  Pathyadi kwata  48ml in 2 divided dose for 2 weeks andAgnikarma during pain phase followed by  withwhich oral administration of  Pathyadikwata  48ml in 2 divided dose for 2 weeksArdhavabhedaka ( Migraine ) conducted in single center.

研究设计

研究类型
Interventional
分配方式
Not Applicable
盲法
Open Label

入排标准

年龄范围
20.00 Year(s) 至 45.00 Year(s)(—)
性别
All

入选标准

  • 1.Patients between 20-45 years of age irrespective of sex, religion, occupation and socio -economic status and willing to participate and provide consent will be included 2.Patient having minimum of one episode of headache in 7 days 3.Patients with signs and symptoms of Ardhavabhedaka and migraine 4.Patients attending OPD during Vegavastha of Ardhavabhedaka (Pain Phase of Migraine).

排除标准

  • 1.Patients contraindicated for Agnikarma and Raktha mokshana as per classics.
  • 2.Patients with other primary headache like tension, cluster headache
  • Patients associated with secondary headache due to Glaucoma, Frontal sinusitis.
  • 4.Patients with Systemic disorders ( Diabetes Mellitus, Hypertension).

结局指标

主要结局

Migraine

时间窗: one month

4.Improvement changes in Midas

时间窗: one month

Questionnaire

时间窗: one month

3.Sustained effect of treatment in

时间窗: one month

5.A cost effective procedure which can be easily practiced

时间窗: one month

during pain phase

时间窗: one month

1.Improvement in the Subjective

时间窗: one month

and objective parameters

时间窗: one month

2.Improvementinthe HIT-6

时间窗: one month

reducingtheepisodesof

时间窗: one month

次要结局

未报告次要终点

研究者

发起方
未提供

研究点 (1)

Loading locations...

相似试验